

☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>GADICKE ANSBERT</u> (Last) (First) (Middle) <u>C/O MPM CAPITAL</u> <u>450 KENDALL STREET</u> (Street) <u>CAMBRIDGE</u> <u>MA</u> <u>02142</u> (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>iTeos Therapeutics, Inc. [ITOS]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) <u>09/16/2021</u>	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person <input checked="" type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	09/16/2021		S ⁽¹⁾		35,565 ⁽²⁾⁽³⁾	D	\$28.47 ⁽⁴⁾	5,693,358	I	See Footnote ⁽⁵⁾
Common Stock	09/17/2021		S ⁽¹⁾		76,473 ⁽⁶⁾	D	\$28.82 ⁽⁷⁾	5,616,885	I	See Footnote ⁽⁸⁾
Common Stock	09/20/2021		S ⁽¹⁾		17,743 ⁽⁹⁾	D	\$27.03 ⁽¹⁰⁾	5,599,142	I	See Footnote ⁽¹¹⁾
Common Stock	09/20/2021		S ⁽¹⁾		22,930 ⁽¹²⁾	D	\$27.84 ⁽¹³⁾	5,576,212	I	See Footnote ⁽¹⁴⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V		Date Exercisable	Expiration Date					

1. Name and Address of Reporting Person* <u>GADICKE ANSBERT</u> (Last) (First) (Middle) <u>C/O MPM CAPITAL</u> <u>450 KENDALL STREET</u> (Street) <u>CAMBRIDGE</u> <u>MA</u> <u>02142</u> (City) (State) (Zip)
1. Name and Address of Reporting Person* <u>UBS Oncology Impact Fund L.P.</u> (Last) (First) (Middle) <u>C/O MPM CAPITAL</u> <u>450 KENDALL STREET</u> (Street) <u>CAMBRIDGE</u> <u>MA</u> <u>02142</u>

(City)	(State)	(Zip)
1. Name and Address of Reporting Person*		
BioImpact Capital LLC		
(Last)	(First)	(Middle)
C/O MPM CAPITAL		
450 KENDALL STREET		
(Street)		
CAMBRIDGE	MA	02142
(City)	(State)	(Zip)
1. Name and Address of Reporting Person*		
Oncology Impact Fund (Cayman) Management L.P.		
(Last)	(First)	(Middle)
C/O MPM CAPITAL		
450 KENDALL STREET		
(Street)		
CAMBRIDGE	MA	02142
(City)	(State)	(Zip)

Explanation of Responses:

1. Transaction effected pursuant to a plan established pursuant to Rule 10b5-1.
2. The shares were sold as follows: 12,662 by MPM BioVentures 2014, L.P. ("BV 2014"), 436 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 7,997 by MPM BioVentures 2018, L.P. ("BV 2018"), 158 by MPM Asset Management Investors BV2018 LLC ("AM BV2018") and 14,312 by UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV 2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV 2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV 2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Ansbert Gadick is a managing director of BV 2014 LLC and BV 2018 LLC.
3. BioImpact Capital LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology Impact Fund, L.P. Ansbert Gadick is a managing partner of BioImpact. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any.
4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$27.885 to \$28.69 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
5. The shares are held as follows: 1,969,301 by BV 2014, 107,713 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 67,782 by AM BV2014, 1,243,769 by BV 2018, 54,213 by MPM BioVentures 2018(B), L.P. ("BV 2018(B)"), 24,545 by AM BV2018 and 2,226,035 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any.
6. The shares were sold as follows: 27,226 by BV 2014, 937 by AM BV2014, 17,195 by BV 2018, 340 by AM BV2018 and 30,775 by UBS Oncology.
7. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$28.50 to \$29.11 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
8. The shares are held as follows: 1,942,075 by BV 2014, 107,713 by BV 2014(B), 66,845 by AM BV2014, 1,226,574 by BV 2018, 54,213 by BV 2018(B), 24,205 by AM BV2018 and 2,195,260 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any.
9. The shares were sold as follows: 6,317 by BV 2014, 217 by AM BV2014, 3,990 by BV 2018, 78 by AM BV2018 and 7,141 by UBS Oncology.
10. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$26.535 to \$27.52 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
11. The shares are held as follows: 1,935,758 by BV 2014, 107,713 by BV 2014(B), 66,628 by AM BV2014, 1,222,584 by BV 2018, 54,213 by BV 2018(B), 24,127 by AM BV2018 and 2,188,119 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any.
12. The shares were sold as follows: 8,163 by BV 2014, 281 by AM BV2014, 5,156 by BV 2018, 101 by AM BV2018 and 9,229 by UBS Oncology.
13. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$27.53 to \$28.39 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
14. The shares are held as follows: 1,927,595 by BV 2014, 107,713 by BV 2014(B), 66,347 by AM BV2014, 1,217,428 by BV 2018, 54,213 by BV 2018(B), 24,026 by AM BV2018 and 2,178,890 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any.

Remarks:

[/s/ Ansbert Gadick](#) [09/20/2021](#)
[/s/ Ansbert Gadick, managing partner of BioImpact Capital LLC, the general partner of Oncology Impact Fund \(Cayman\) Management L.P., the general partner of UBS Oncology Impact Fund L.P](#) [09/20/2021](#)
[/s/ Ansbert Gadick, managing partner of BioImpact Capital LLC](#) [09/20/2021](#)
[/s/ Ansbert Gadick, managing partner of BioImpact Capital LLC, the general partner of Oncology Impact Fund \(Cayman\) Management L.P.](#) [09/20/2021](#)

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.